Literature DB >> 6424948

Lymphokine-mediated activation of human monocytes: neutralization by monoclonal antibody to interferon-gamma.

J Le, J Vilcek.   

Abstract

Purified natural and recombinant human immune interferon (IFN-gamma) were found to activate human monocytes from peripheral blood to exert enhanced cytotoxicity against human colon adenocarcinoma HT-29 cells. A marked monocyte activation was observed at low concentrations (1 and 10 U/ml) of IFN-gamma. Marked monocyte activation was also obtained with two lymphokine preparations, produced in peripheral blood mononuclear cell (PBM) cultures induced with phytohemagglutinin (PHA) or by combined stimulation with PHA and 12-O-tetradecanoylphorbol 13-acetate (TPA). The component responsible for macrophage activation in such lymphokine preparations in the past was considered to be "macrophage-activating factor" (MAF). When monoclonal antibody specifically neutralizing IFN-gamma was added to these lymphokine preparations, all MAF activity disappeared, indicating that IFN-gamma is the sole protein showing MAF activity in these preparations.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6424948     DOI: 10.1016/0008-8749(84)90299-5

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  12 in total

1.  A phase I study of recombinant interferon gamma administered by s.c. injection three times per week in patients with solid tumours.

Authors:  J Wagstaff; D Smith; P Nelmes; P Loynds; D Crowther
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Monocytes and polymorphonuclear neutrophils of patients with streptococcal pharyngitis express increased numbers of type I IgG Fc receptors.

Authors:  P M Guyre; A S Campbell; W D Kniffin; M W Fanger
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

3.  Use of monoclonal antibodies as sensitive and specific probes for biologically active human gamma-interferon.

Authors:  T W Chang; S McKinney; V Liu; P C Kung; J Vilcek; J Le
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

4.  Transfected Plasmodium knowlesi produces bioactive host gamma interferon: a new perspective for modulating immune responses to malaria parasites.

Authors:  Hastings Ozwara; Jan A M Langermans; Clemens H M Kocken; Annemarie van der Wel; Peter H van der Meide; Richard A W Vervenne; Jason M Mwenda; Alan W Thomas
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

5.  Release of cytokines induced by Salmonella typhimurium porins.

Authors:  F Galdiero; G C de L'ero; N Benedetto; M Galdiero; M A Tufano
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

6.  Recombinant and natural gamma-interferon activation of macrophages in vitro: different dose requirements for induction of killing activity against phagocytizable and nonphagocytizable fungi.

Authors:  E Brummer; C J Morrison; D A Stevens
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

7.  Activation of monocytes by interferon-gamma has no effect on the level or affinity of the nicotinamide adenine dinucleotide-phosphate oxidase and on agonist-dependent superoxide formation.

Authors:  M Thelen; M Wolf; M Baggiolini
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

8.  Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection.

Authors:  N A Buchmeier; R D Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

9.  The role of monocyte cytotoxic factor (CF) in cytostasis mediated by IFN-gamma-activated monocytes.

Authors:  O Kildahl-Andersen; J Nissen-Meyer
Journal:  Immunology       Date:  1985-10       Impact factor: 7.397

10.  Human lymphokine preparations which generate tumoricidal properties of human monocytes in vitro may be distinct from gamma interferon.

Authors:  E S Kleinerman; R H Wiltrout; R Zicht; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.